Current issue
Archive
Online first
About the Journal
Editorial Office
Editorial Board
Publisher
Editorial Policies
Ethical standards and procedures
Abstracting and indexing
Reviewers
Honorary Reviewers
Subscription
Contact
Most read articles
Instructions for authors
Article processing charge (APC)
Books and Events
Books
Events
CASE-BASED REVIEW
Giant cell arteritis presenting as a stroke in the internal carotid artery territory: a case-based review
1
Department of Medicine, Surgery and Neurosciences, Rheumatology Unit, University of Siena, Italy
Submission date: 2021-01-20
Final revision date: 2021-02-19
Acceptance date: 2021-02-22
Online publication date: 2021-04-27
Publication date: 2021-04-28
Reumatologia 2021;59(2):121-125
KEYWORDS
TOPICS
ABSTRACT
Giant cell arteritis (GCA) is a large-vessel vasculitis, typically affecting the aorta and its branches. The involvement of vertebral and internal carotid arteries occurs in a limited number of cases, and stroke as a presenting symptom of GCA is extremely unusual: this subset of the disease has a poor prognosis and rarely responds to immunosuppression.
We report the case of a 70-year-old woman, who presented to the Emergency Department for ischemic stroke, which appeared to be the first and only symptom of GCA. The prompt administration of steroids and tocilizumab (TCZ) led to clinical and radiological resolution, with no residual disability at 6-month follow-up.
Our case-based review, highlighting the rarity of a large vessel vasculitis presenting only with a cerebrovascular accident, provides new evidence for the efficacy of TCZ even in more unusual varieties of GCA: in these cases, TCZ should be immediately prescribed, in order to prevent mortality and severe long-term morbidity.
We report the case of a 70-year-old woman, who presented to the Emergency Department for ischemic stroke, which appeared to be the first and only symptom of GCA. The prompt administration of steroids and tocilizumab (TCZ) led to clinical and radiological resolution, with no residual disability at 6-month follow-up.
Our case-based review, highlighting the rarity of a large vessel vasculitis presenting only with a cerebrovascular accident, provides new evidence for the efficacy of TCZ even in more unusual varieties of GCA: in these cases, TCZ should be immediately prescribed, in order to prevent mortality and severe long-term morbidity.
REFERENCES (27)
1.
Salvarani C, Giannini C, Miller DV, Hunder G. Giant cell arteritis: involvement of intracranial arteries. Arthritis Rheum 2006; 55: 985–989, DOI: 10.1002/art.22359.
2.
Alsolaimani RS, Bhavsar SV, Khalidi NA, et al. Severe intracranial involvement in giant cell arteritis: 5 cases and literature review. J Rheumatol 2016; 43: 648–656, DOI: 10.3899/jrheum. 150143.
3.
Cid MC, Font C, Oristrell J, et al. Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. Arthritis Rheum 1998; 41: 26–32, DOI: 10.1002/1529-0131(199801)41:1<26::AID-ART4>3.0.CO;2-0.
4.
Pariente A, Guédon A, Alamowitch S, et al. Ischemic stroke in giant-cell arteritis: French retrospective study. J Autoimmun 2019; 99: 48–51, DOI: 10.1016/j.jaut.2019.01.009.
5.
Salvarani C, Della Bella C, Cimino L, et al. Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis. Rheumatology (Oxford) 2009; 48: 250–253, DOI: 10.1093/rheumatology/ken465.
6.
Gonzalez-Gay MA, Vazquez-Rodriguez TR, Gomez-Acebo I, et al. Strokes at time of disease diagnosis in a series of 287 patients with biopsy-proven giant cell arteritis. Medicine (Baltimore) 2009; 88: 227–235, DOI: 10.1097/MD.0b013e3181af4518.
7.
Lee MS, Smith SD, Galor A, Hoffman GS. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum 2006; 54: 3306–3309, DOI: 10.1002/art.22141.
8.
Guisado-Alonso D, Edo MC, Estrada Alarcón PV, et al. Progression of large vessel disease in patients with giant cell arteritis-associated ischemic stroke: the role of vascular imaging: a case series. J Clin Rheumatol 2020, DOI: 10.1097/RHU. 0000000000001498 [Online ahead of print].
9.
Larivière D, Sacre K, Klein I, et al. Extra- and intracranial cerebral vasculitis in giant cell arteritis: an observational study. Medicine (Baltimore) 2014; 93: e265, DOI: 10.1097/MD.0000000000000265.
10.
Howard GF 3rd, Ho SU, Kim KS, Wallach J. Bilateral carotid artery occlusion resulting from giant cell arteritis. Ann Neurol 1984; 15: 204–207, DOI: 10.1002/ana.410150216.
11.
Solans-Laqué R, Bosch-Gil JA, Molina-Catenario CA, et al. Stroke and multi-infarct dementia as presenting symptoms of giant cell arteritis: report of 7 cases and review of the literature. Medicine (Baltimore) 2008; 87: 335–344, DOI: 10.1097/MD.0b013e3181908e96.
12.
Elhfnawy AM, Bieber M, Schliesser M, Kraft P. Atypical presentation of giant cell arteritis in a patient with vertebrobasilar stroke: A case report. Medicine (Baltimore) 2019; 98: e16737, DOI: 10.1097/MD.0000000000016737.
13.
Caselli RJ, Hunder GG, Whisnant JP. Neurologic disease in biopsy-proven giant cell (temporal) arteritis. Neurology 1988; 38: 352–359, DOI: 10.1212/wnl.38.3.352.
14.
Samson M, Jacquin A, Audia S, et al. Stroke associated with giant cell arteritis: a population-based study. J Neurol Neurosurg Psychiatry 2015; 86: 216–221, DOI: 10.1136/jnnp-2014-307614.
15.
Nesher G, Berkun Y, Mates M, et al. Risk factors for cranial ischemic complications in giant cell arteritis. Medicine (Baltimore) 2004; 83: 114–122, DOI: 10.1097/01.md.0000119761.27564.c9.
16.
de Boysson H, Liozon E, Larivière D, et al. Giant cell arteritis-related stroke: a retrospective multicenter case-control study. J Rheumatol 2017; 44: 297–303, DOI: 10.3899/jrheum.161033.
17.
Zenone T, Puget M. Characteristics of cerebrovascular accidents at time of diagnosis in a series of 98 patients with giant cell arteritis. Rheumatol Int 2013; 33: 3017–3023, DOI: 10.1007/s00296-013-2814-0.
18.
Cull RE. Internal carotid artery occlusion caused by giant cell arteritis. J Neurol Neurosurg Psychiatry 1979; 42: 1066–1067, DOI: 10.1136/jnnp.42.11.1066.
19.
Wilkinson IM, Russell RW. Arteries of the head and neck in giant cell arteritis. A pathological study to show the pattern of arterial involvement. Arch Neurol 1972; 27: 378–391, DOI: 10.1001/archneur.1972.00490170010003.
20.
Healy S, Simpson M, Kitchen WJ, et al. Steroid refractory giant cell arteritis with bilateral vertebral artery occlusion and middle cerebellar peduncle infarction. J R Coll Physicians Edinb 2019; 49: 118–121, DOI: 10.4997/JRCPE.2019.206.
21.
Chomlak DR, Ghazanfari F, Datta M. Case study: giant cell arteritis with vertebral artery stenosis. Clin Med Insights Arthritis Musculoskelet Disord 2016; 9: 103–107, DOI: 10.4137/CMAMD.S38143.
22.
Cox BC, Fulgham JR, Klaas JP. Recurrent stroke in giant cell arteritis despite immunotherapy. Neurologist 2019; 24: 139–141, DOI: 10.1097/NRL.0000000000000237.
23.
Oerding C, Kaden I, Wohlfarth K. Isolated bilateral internal carotid artery stenosis and recurrent ischemic strokes in a patient with suspected giant cell arteritis. Case Rep Neurol 2020; 12: 84–91, DOI: 10.1159/000504018.
24.
Simonsen CZ, Speiser L, Hansen IT, et al. Endovascular treatment of intracerebral giant cell arteritis. Front Neurol 2020; 11: 287, DOI: 10.3389/fneur.2020.00287.
25.
Vassallo C, Ceci Bonello E, Borg A. Giant cell arteritis presenting as multifocal cerebral infarcts. BMJ Case Rep 2020; 13: e236823, DOI: 10.1136/bcr-2020-236823.
26.
Stone JH, Tuckwell K, Dimonaco S, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med 2017; 377: 317–328, DOI: 10.1056/NEJMoa1613849.
27.
Conticini E, Sota J, Falsetti P, et al. The Role of multimodality imaging in monitoring disease activity and therapeutic response to tocilizumab in giant cell arteritis. Mediators Inflamm 2020; 2020: 3203241, DOI: 10.1155/2020/3203241.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
RELATED ARTICLE
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
